Tae-Min Kim

62PUBLICATIONS
342CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Jun 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|Jun 01, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Apr 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

|Apr 13, 2026
Comparative Outcomes of Consolidation Strategies After R-MVP Induction in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Sang-A Kim, Jung Sun Kim, Ji Yun Lee

|Apr 07, 2026
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

Pageof 11

Frequent Collaborators

10 joint publications

Chul-Kee Park

7 joint publications

Sung-Hye Park

6 joint publications

Dong-Wan Kim

6 joint publications

Soon-Tae Lee